Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Sell
49
WST Quote, Financials, Valuation and Earnings
Last price:
$330.25
Seasonality move
:
5.36%
Day range:
$330.33 - $334.33
52-week range:
$265.00 - $413.70
Dividend yield:
0.24%
P/E ratio:
49.44x
P/S ratio:
8.58x
P/B ratio:
8.77x
Volume:
382.8K
Avg. volume:
523.3K
1-year change:
-6.37%
Market cap:
$24.1B
Revenue:
$2.9B
EPS (TTM):
$6.74
Analysts' Opinion
-
Consensus RatingWest Pharmaceutical Services has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $378.17, West Pharmaceutical Services has an estimated upside of 13.49% from its current price of $333.22.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $305.00 representing 100% downside risk from its current price of $333.22.
Fair Value
-
According to the consensus of 9 analysts, West Pharmaceutical Services has 13.49% upside to fair value with a price target of $378.17 per share.
WST vs. S&P 500
-
Over the past 5 trading days, West Pharmaceutical Services has overperformed the S&P 500 by 1.22% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
West Pharmaceutical Services does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
West Pharmaceutical Services revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter West Pharmaceutical Services reported revenues of $746.9M.
Earnings Growth
-
West Pharmaceutical Services earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter West Pharmaceutical Services reported earnings per share of $1.85.
Enterprise value:
23.8B
EV / Invested capital:
8.07x
Price / LTM sales:
8.58x
EV / EBIT:
40.16x
EV / Revenue:
8.29x
PEG ratio (5yr expected):
17.17x
EV / Free cash flow:
74.14x
Price / Operating cash flow:
76.70x
Enterprise value / EBITDA:
32.03x
Gross Profit (TTM):
$1B
Return On Assets:
13.61%
Net Income Margin (TTM):
17.37%
Return On Equity:
18.16%
Return On Invested Capital:
16.89%
Operating Margin:
22.19%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.9B | $2.9B | $2.9B | $747.4M | $746.9M | |
| Gross Profit | $1.2B | $1.1B | $1B | $288.3M | $264.7M | |
| Operating Income | $789.2M | $698.1M | $590.9M | $182.9M | $165.7M | |
| EBITDA | $865.8M | $800.5M | $744.4M | $225.6M | $205.4M | |
| Diluted EPS | $8.29 | $7.41 | $6.74 | $2.14 | $1.85 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2B | $1.6B | $1.7B | $2B | $1.6B | |
| Total Assets | $2.6B | $3.1B | $3.3B | $3.8B | $3.7B | |
| Current Liabilities | $447.7M | $558.6M | $456.7M | $533.5M | $516.5M | |
| Total Liabilities | $863.9M | $940.3M | $846M | $886.5M | $923M | |
| Total Equity | $1.7B | $2.2B | $2.5B | $2.9B | $2.8B | |
| Total Debt | $255.7M | $254.1M | $209.4M | $207.3M | $202.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $654M | $768.2M | $702.4M | $230.1M | $180.1M | |
| Cash From Investing | -$270.8M | -$354.7M | -$382.7M | -$95.7M | -$82.1M | |
| Cash From Financing | -$290.3M | -$279.6M | -$743.2M | -$22.3M | -$64.4M | |
| Free Cash Flow | $387.8M | $420M | $321.6M | $134.3M | $98.8M | |
WST
Sector
Market Cap
$24.1B
$45.9M
Price % of 52-Week High
80.55%
46.95%
Dividend Yield
0.24%
0%
Shareholder Yield
3.44%
-0.6%
1-Year Price Total Return
-6.37%
-32.15%
Beta (5-Year)
1.007
0.772
Dividend yield:
0.24%
Annualized payout:
$0.77
Payout ratio:
11.73%
Growth streak:
31 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$330.87
200-day SMA
Buy
Level
$328.87
Bollinger Bands (100)
Buy
Level
295.27 - 323.95
Chaikin Money Flow
Buy
Level
97.4M
20-day SMA
Buy
Level
$326.54
Relative Strength Index (RSI14)
Buy
Level
58.26
ADX Line
Buy
Level
9.47
Williams %R
Neutral
Level
-23.266
50-day SMA
Buy
Level
$319.36
MACD (12, 26)
Buy
Level
3.88
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
71.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (19.4355)
Buy
CA Score
(Annual)
Level (1.8381)
Buy
Beneish M-Score
(Annual)
Level (-2.8016)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-3.8368)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
West Pharmaceutical Services is based in Pennsylvania, us, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Stock Forecast FAQ
In the current month, WST has received 6 Buy ratings 3 Hold ratings, and 0 Sell ratings. The WST average analyst price target in the past 3 months is $378.17.
-
Where Will West Pharmaceutical Services Stock Be In 1 Year?
According to analysts, the consensus estimate is that West Pharmaceutical Services share price will rise to $378.17 per share over the next 12 months.
-
What Do Analysts Say About West Pharmaceutical Services?
Analysts are divided on their view about West Pharmaceutical Services share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that West Pharmaceutical Services is a Sell and believe this share price will drop from its current level to $305.00.
-
What Is West Pharmaceutical Services's Price Target?
The price target for West Pharmaceutical Services over the next 1-year time period is forecast to be $378.17 according to 9 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is WST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for West Pharmaceutical Services is a Buy. 6 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of WST?
You can purchase shares of West Pharmaceutical Services via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase West Pharmaceutical Services shares.
-
What Is The West Pharmaceutical Services Share Price Today?
West Pharmaceutical Services was last trading at $330.25 per share. This represents the most recent stock quote for West Pharmaceutical Services. Yesterday, West Pharmaceutical Services closed at $333.22 per share.
-
How To Buy West Pharmaceutical Services Stock Online?
In order to purchase West Pharmaceutical Services stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 2.82% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 11.17% over the past day.
Sell
39
DOGZ alert for Dec 30
Dogness (International) [DOGZ] is up 3.61% over the past day.
